Aspirin-exacerbated respiratory disease: Evaluation and management

Allergy, Asthma and Immunology Research

Volumn 3, Issue 1, 2010, Pages 3-10

  Lee, Rachel U ^a   Stevenson, Donald D ^b  

^a NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

Aspirin desensitization; Aspirin sensitivity; Aspirin exacerbated respiratory disease; Asthma; Chronic sinusitis; Nasal polyps; Samter's triad

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; ETODOLAC; ETORICOXIB; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LUMIRACOXIB; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NIMESULIDE; OXAPROZIN; PARECOXIB; PIROXICAM; ROFECOXIB; SALSALATE; SULINDAC; TOLMETIN; VALDECOXIB;

ASPIRIN EXACERBATED RESPIRATORY DISEASE; AVOIDANCE BEHAVIOR; CLINICAL EVALUATION; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DESENSITIZATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; HUMAN; HYPOTENSION; MORNING DOSAGE; NOSE POLYP; PATIENT SELECTION; PEDIATRICS; REVIEW; STOMACH PAIN; URTICARIA;

EID: 78650647296     PISSN: 20927355     EISSN: 20927363     Source Type: Journal    
DOI: 10.4168/aair.2011.3.1.3     Document Type: Review

References (46)

1. Szczeklik A, Nizankowska-Mogilnicka E, Sanak M. Hypersensitivity to aspirin and non-steroidal anti-inflammatory drugs. In: Adkinson NF Jr, Bochner BS, Busse WW, Holgate ST, Lemanske RF Jr, Simons FER, editors. Middleton's allergy: principles and practice. 7th ed. New York: Mosby; 2009. 1227-40.
2. Stevenson DD. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep 2009;9:155-63.
3. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434.
4. McDonald JR, Mathison DA, Stevenson DD. Aspirin intolerance in asthma. Detection by oral challenge. J Allergy Clin Immunol 1972;50:198-207.
5. Weber RW, Hoffman M, Raine DA Jr, Nelson HS. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979;64:32-7.
6. Delaney JC. The diagnosis of aspirin idiosyncrasy by analgesic challenge. Clin Allergy 1976;6:177-81.
7. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002;89:474-8.
8. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspi-rin-Induced Asthma. Eur Respir J 2000;16:432-6.
9. Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975-83.
10. Widal MF, Abrami P, Lermeyez J. Idiosyncratic anaphylaxis. Presse Med 1922;30:189-92.
11. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006;118:773-86.
12. Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacer-bated respiratory disease. Ann Allergy Asthma Immunol 2005;94:652-7.
13. Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol 2003;24:159-68.
14. Pfaar O, Klimek L. Eicosanoids, aspirin-intolerance and the upper airways-current standards and recent improvements of the desensitization therapy. J Physiol Pharmacol 2006;57 Suppl 12:5-13.
15. Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1998;101:581-6.
16. Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000;15:863-9.
17. Parikh AA, Scadding GK. Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope 2005;115:1385-90.
18. Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 2008;100:420-5.
19. Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J, Nizankowska E, Isakson PC, Mejza F, Lefkowith JB, Dahlén SE, Szczeklik A, Murray JJ, Dahlen B. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003;111:1116-21.
20. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002;46:2201-6.
21. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108:47-51.
22. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspi-rin-exacerbated respiratory disease. J Allergy Clin Immunol 2003;111:180-6.
23. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996;98:751-8.
24. Kowalski ML, Grzelewska-Rzymowska I, Szmidt M, Rozniecki J. Clinical efficacy of aspirin in "desensitised" aspirin-sensitive asthmatics. Eur J Respir Dis 1986;69:219-25.
25. Klimek L, Pfaar O. Aspirin intolerance: does desensitization alter the course of the disease? Immunol Allergy Clin North Am 2009;29:669-75.
26. McMains KC, Kountakis SE. Medical and surgical considerations in patients with Samter's triad. Am J Rhinol 2006;20:573-6.
27. Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003;90:338-41.
28. Shaker M, Lobb A, Jenkins P, O'Rourke D, Takemoto SK, Sheth S, Burroughs T, Dykewicz MS. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2008;121:81-7.
29. Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol 2006;118:801-4.
30. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, Simon RA, Wald J, Woessner KM. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol 2007;98:172-4.
31. Daffern PJ, Muilenburg D, Hugli TE, Stevenson DD. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 1999;104:559-64.
32. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-51.
33. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347:1493-9.
34. Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, Lee TH. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025-9.
35. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002;32:1491-6.
36. Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M, Lumry WR, Picado C, Stevenson DD, Bousquet J, Pauwels R, Holgate ST, Shahane A, Zhang J, Reiss TF, Szczeklik A. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.
37. White A, Ludington E, Mehra P, Stevenson DD, Simon RA. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol 2006;97:688-93.
38. White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005;95:330-5.
39. Williams AN, Simon RA, Woessner KM, Stevenson DD. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol 2007;120:273-7.
40. Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2009;123:406-10.
41. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacer-bated respiratory disease. J Allergy Clin Immunol 2007;119:157-64.
42. Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H, Keck T. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008;63:1228-34.
43. Lee RU, White D, Ding D, Durson AB, Woessner KM, Simon RA, Stevenson DD. Intranasal ketorolac and modified oral aspirin challenge enhances desensitization in aspirin exacerbated respiratory disease. Ann Allergy Asthma Immunol 2010;105:130-5.
44. White A, Bigby T, Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006;97:190-5.
45. Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000;55:921-4.
46. Patriarca G, Bellioni P, Nucera E, Schiavino D, Papa G, Schinco G, Fais G, Pirotta LR. Intranasal treatment with lysine acetylsalicylate in patients with nasal polyposis. Ann Allergy 1991;67:588-92.